Samuel Alvarez-Arguedas

Samuel Alvarez-Arguedas

Auto-generated profile, based on publicly available information

Samuel Alvarez-Arguedas

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Virulence
Verified
Journal Article
Open access
KRKathryn C. Rahlwes
Kathryn C. Rahlwes
BDBeatriz Rocha Simões Dias
Beatriz Rocha Simões Dias
PCPriscila C. Campos
Priscila C. Campos
SASamuel Alvarez-Arguedas
Samuel Alvarez-Arguedas
MSMichael U. Shiloh
Michael U. Shiloh
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, an infectious disease with one of the highest morbidity and mortality rates worldwide. Leveraging its highly evolved repertoire of non-protein and protein virulence factors, Mtb invades through the airway, subverts host immunity, establishes its survival niche, and ultimately escapes in the setting of active disease to initiate another round of infection in a naïve host. In this review, we will provide a concise synopsis of the infectious life cycle of Mtb and its clinical and epidemiologic significance. We will also take stock of its virulence factors and pathogenic mechanisms that modulate host immunity and facilitate its spread. Developing a greater understanding of the interface between Mtb virulence factors and host defenses will enable progress towards improved vaccines and therapeutics to prevent and treat tuberculosis.

22 October 2015 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
NANacho Aguilo
Nacho Aguilo
SASamuel Alvarez-Arguedas
Samuel Alvarez-Arguedas
SUSantiago Uranga
Santiago Uranga
DMDessislava Marinova
Dessislava Marinova
MMMarta Monzón
Marta Monzón
CMCarlos Martin
Carlos Martin
Some of the most promising novel tuberculosis vaccine strategies currently under development are based on respiratory vaccination, mimicking the natural route of infection. In this work, we have compared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-susceptible DBA/2 mouse strain, a model in which parenterally administered BCG vaccine does not protect against tuberculosis. Our data show that intranasally but not subcutaneously administered BCG confers robust protection against pulmonary tuberculosis challenge. In addition, our results indicate that pulmonary vaccination triggers a Mycobacterium tuberculosis–specific mucosal immune response orchestrated by interleukin 17A (IL-17A). Thus, IL-17A neutralization in vivo reduces protection and abrogates M. tuberculosis–specific immunoglobulin A (IgA) secretion to respiratory airways and lung expression of polymeric immunoglobulin receptor induced following intranasal vaccination. Together, our results demonstrate that pulmonary delivery of BCG can overcome the lack of protection observed when BCG is given parenterally, suggesting that respiratory tuberculosis vaccines could have an advantage in tuberculosis-endemic countries, where intradermally administered BCG has inefficient effectiveness against pulmonary tuberculosis.

14 July 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
NANacho Aguilo
Nacho Aguilo
JGJesus Gonzalo-Asensio
Jesus Gonzalo-Asensio
SASamuel Alvarez-Arguedas
Samuel Alvarez-Arguedas
DMDessislava Marinova
Dessislava Marinova
AGAna Belen Gomez
Ana Belen Gomez
CMCarlos Martin
Carlos Martin
MTBVAC is a live-attenuated Mycobacterium tuberculosis vaccine, currently under clinical development, that contains the major antigens ESAT6 and CFP10. These antigens are absent from the current tuberculosis vaccine, BCG. Here we compare the protection induced by BCG and MTBVAC in several mouse strains that naturally express different MHC haplotypes differentially recognizing ESAT6 and CFP10. MTBVAC induces improved protection in C3H mice, the only of the three tested strains reactive to both ESAT6 and CFP10. Deletion of both antigens in MTBVAC reduces its efficacy to BCG levels, supporting a link between greater efficacy and CFP10- and ESAT6-specific reactogenicity. In addition, MTBVAC (but not BCG) triggers a specific response in human vaccinees against ESAT6 and CFP10. Our results warrant further exploration of this response as potential biomarker of protection in MTBVAC clinical trials.

5 March 2020 in eLife
Verified
Journal Article
Open access
HKHaaris S Khan
Haaris S Khan
VNVidhya R Nair
Vidhya R Nair
CRCody R Ruhl
Cody R Ruhl
SASamuel Alvarez-Arguedas
Samuel Alvarez-Arguedas
JRJorge L Galvan Rendiz
Jorge L Galvan Rendiz
MSMichael U Shiloh
Michael U Shiloh
Mycobacterium tuberculosis (Mtb) can enter the body through multiple routes, including via specialized transcytotic cells called microfold cells (M cell). However, the mechanistic basis for M cell entry remains undefined. Here, we show that M cell transcytosis depends on the Mtb Type VII secretion machine and its major virulence factor EsxA. We identify scavenger receptor B1 (SR-B1) as an EsxA receptor on airway M cells. SR-B1 is required for Mtb binding to and translocation across M cells in mouse and human tissue. Together, our data demonstrate a previously undescribed role for Mtb EsxA in mucosal invasion and identify SR-B1 as the airway M cell receptor for Mtb.

22 August 2012 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
BRBeatriz Ranera
Beatriz Ranera
ARAna Rosa Remacha
Ana Rosa Remacha
SÁSamuel Álvarez-Arguedas
Samuel Álvarez-Arguedas
ARAntonio Romero
Antonio Romero
Paco VázquezPaco Vázquez
Paco Vázquez
CRClementina Rodellar
Clementina Rodellar
Mesenchymal stem cells (MSCs) derived from bone marrow (BM-MSCs) and adipose tissue (AT-MSCs) are being applied to equine cell therapy. The physiological environment in which MSCs reside is hypoxic and does not resemble the oxygen level typically used in in vitro culture (20% O2). This work compares the growth kinetics, viability, cell cycle, phenotype and expression of pluripotency markers in both equine BM-MSCs and AT-MSCs at 5% and 20% O2. At the conclusion of culture, fewer BM-MSCs were obtained in hypoxia than in normoxia as a result of significantly reduced cell division. Hypoxic AT-MSCs proliferated less than normoxic AT-MSCs because of a significantly higher presence of non-viable cells during culture. Flow cytometry analysis revealed that the immunophenotype of both MSCs was maintained in both oxygen conditions. Gene expression analysis using RT-qPCR showed that statistically significant differences were only found for CD49d in BM-MSCs and CD44 in AT-MSCs. Similar gene expression patterns were observed at both 5% and 20% O2 for the remaining surface markers. Equine MSCs expressed the embryonic markers NANOG, OCT4 and SOX2 in both oxygen conditions. Additionally, hypoxic cells tended to display higher expression, which might indicate that hypoxia retains equine MSCs in an undifferentiated state. Hypoxia attenuates the proliferative capacity of equine MSCs, but does not affect the phenotype and seems to keep them more undifferentiated than normoxic MSCs.

6 July 2012 in The Veterinary Journal
Verified
Journal Article
Closed access
BRBeatriz Ranera
Beatriz Ranera
ARAna Rosa Remacha
Ana Rosa Remacha
SÁSamuel Álvarez-Arguedas
Samuel Álvarez-Arguedas
TCTomás Castiella
Tomás Castiella
FVFrancisco José Vázquez
Francisco José Vázquez
CRClementina Rodellar
Clementina Rodellar